On August 31, 2021 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that management will be participating in fireside chats at the following investor conferences (Press release, Sangamo Therapeutics, AUG 31, 2021, View Source [SID1234587051]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Virtual Wells Fargo Healthcare Conference
Date: Friday, September 10th at 3:20 p.m. Eastern Time
H.C. Wainwright & Co. 23rd Annual Global Investment Conference
Date: Monday, September 13th at 7:00 a.m. Eastern Time
Morgan Stanley 19th Annual Global Healthcare Conference
Date: Wednesday, September 15th at 10:15 a.m. Eastern Time
For presentations that are webcast live, an access link will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website after the event.

On August 31, 2021 Exact Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision medicine company evaluating Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, reported that its Chief Executive Officer, Dr Rafiq Hasan, will be presenting at the Pareto Securities 12th Annual Healthcare Conference on Wednesday, 1 September at 12.00pm CET (Press release, Exact Therapeutics, AUG 31, 2021, View Source [SID1234587049]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About EXACT-Tx

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT). ACT sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com

About ACT

ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.

ACT is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.

Initial focus of the company is oncology, however the ACT platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.

On August 31, 2021 Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, reported that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, reported that it will participate in a fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Tuesday, September 14, at 3:30 p.m. Eastern Time (Press release, Veracyte, AUG 31, 2021, View Source [SID1234587048]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at View Source Replays of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

On August 31, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2021, which is being held from September 16-21, 2021 (Press release, Phio Pharmaceuticals, AUG 31, 2021, View Source [SID1234587047]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Event:

ESMO Virtual Congress 2021

Title:

Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors

Authors:

Benjamin Cuiffo, et al.

Abstract Number:

#4154

Date:

September 16-21, 2021

An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company’s website (click here)

On August 31, 2021 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported that it will present at the following virtual healthcare investor conferences in September (Press release, Intellia Therapeutics, AUG 31, 2021, View Source [SID1234587046]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thursday, September 9, 2021
Wells Fargo Healthcare Conference
Time: 10:40 am ET

Monday, September 13, 2021
H.C. Wainwright 23rd Annual Global Investment Conference
Time: 7:00 am ET

A live webcast of Intellia’s presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each presentation.